SCHEMBL7934112

SCHEMBL7934112

Nc1ncccc1NCc1cc(NC(=O)c2cc3cccn3cn2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.47
CBLB Q13191 1/20 0.43
PRKCI P41743 3/20 0.40
CHRNA7 P36544 1/20 0.38
GSK3B P49841 1/20 0.35
SHMT2 P34897 1/20 0.34
GRM4 Q14833 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KIT P10721 2/20 0.34
BRAF P15056 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7946616 0.88 BACE1 (0.61) BACE1CBLBCHRNA7GRM4HDAC4
SCHEMBL7940557 0.87 BACE1 (0.45) BACE1PRKCISHMT2GRM4KDM4E
SCHEMBL7934113 0.85 BACE1 (0.51) BACE1CBLBCHRNA7GRM4HDAC3
SCHEMBL7942040 0.83 KDM4E (0.54) BACE1KDM4EHSD17B10
SCHEMBL7944269 0.80 BACE1 (0.48) BACE1PRKCISHMT2GRM4KIT
SCHEMBL7943492 0.79 BACE1 (0.52) BACE1CBLBPRKCIKITBRAF
SCHEMBL7935620 0.79 BACE1 (0.53) BACE1PRKCIGSK3BSHMT2GRM4
SCHEMBL7941379 0.79 BACE1 (0.53) BACE1PRKCIGRM4
SCHEMBL7942025 0.78 BACE1 (0.43) BACE1PRKCIKDM4EHSD17B10
SCHEMBL7940383 0.78 BACE1 (0.49) BACE1PRKCIKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885CBLB 3817/4885PRKCI 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.